Clinical trials
Alzheimer clinical trials
Below are recruiting alzheimer clinical trials, each written for real people, not researchers. We’re tracking 633 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06439992Recruiting
New PET scan tracer to detect Alzheimer's in the brain
This study tests a new PET imaging tracer called Fluselenamyl to see how well it shows amyloid plaques (a protein linked to Alzheimer's) in the brain. It may help improve early diagnosis for people with Alzheimer's or support research in healthy volunteers.
St Louis, MissouriAges 18 years+ - NCT06362707RecruitingPhase 2
Fasudil trial for early Alzheimer's disease
This trial tests a medication called fasudil to see if it can help people with early Alzheimer's disease. It is for people who have early symptoms (mild cognitive impairment or mild dementia) and have biomarker evidence of Alzheimer's in their brain.
Tromsø, NordlandAges 50–100 - NCT06338397Recruiting
Social and emotional thinking in Alzheimer's
This study looks at how Alzheimer's disease and similar conditions affect social and emotional thinking. Researchers will use brain scans and questionnaires to understand these changes better.
LilleAges 40–85 - NCT06322667Recruiting
Study of lecanemab in early Alzheimer's disease
This study tracks the real-world experience of people with early Alzheimer's disease who are already taking lecanemab. It aims to better understand how the medication works and its safety in everyday medical practice.
HiroshimaAges 18 years+ - NCT06297590RecruitingPhase 1
First human study of a new Alzheimer's drug
This study tests an experimental drug (LY3954068) for people with early Alzheimer's disease. It aims to see if the drug is safe and may slow memory loss. You'll need a PET scan to measure tau protein in the brain and have a study partner who can help attend appointments.
Maitland, FloridaAges 50–85 - NCT06313944Recruiting
German registry of Alzheimer's treated with sound wave therapy
This trial is a registry that collects information about people with Alzheimer's disease who receive a treatment called transcranial pulse stimulation (TPS), which uses gentle sound waves to stimulate the brain. The goal is to track safety and how well it works over time.
Potsdam, BrandenburgAges 18–85 - NCT06274528RecruitingPhase 2
DORA and lemborexant in Alzheimer's biomarkers study
This study is testing whether a sleep medication called lemborexant can improve sleep and reduce Alzheimer's-related proteins in healthy older adults with no memory problems. It could help find new ways to delay or prevent Alzheimer's disease.
St Louis, MissouriAges 65 years+ - NCT06230783Recruiting
Speech test for early Alzheimer's detection
This trial uses speech pattern analysis to detect early signs of Alzheimer's. If you're already in a Wisconsin Alzheimer's study, you may help test if your voice can reveal memory changes.
Madison, WisconsinAges 40–80 - NCT06189963RecruitingPhase 1/Phase 2
Cell therapy trial for moderate Alzheimer's disease
This trial tests a new immune cell therapy (SNK01) for people with moderate Alzheimer's disease. The goal is to see if it can slow down memory and thinking decline.
Glendale, CaliforniaAges 40–85 - NCT06194799Enrolling by invitationPhase 3
Long-term ACP-204 for Alzheimer's psychosis
This study tests a long-term medicine (ACP-204) for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). If you took part in the earlier ACP-204 study, this open-label extension lets you continue receiving the medicine to see how well it works over time.
Costa Mesa, CaliforniaAges 55–95 - NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
Chandler, ArizonaAges 55–95 - NCT06129838Recruiting
Inflammation in Alzheimer's disease using a brain scan
This study uses a special PET scan to look for inflammation in the brains of people with Alzheimer's or related dementias. It may help researchers understand how inflammation affects memory and thinking problems.
St Louis, MissouriAges 50 years+ - NCT06088121Recruiting
TMS with cognitive training for mild Alzheimer's dementia
This study tests a combination of brain stimulation (TMS) and cognitive training to improve memory and thinking in people with mild Alzheimer's. It may help if you are already on a stable dose of a donepezil-type medication and have a confirmed Alzheimer's diagnosis.
Incheon, Bupyeong 6(yuk)-dong, Bupyeong-guAges 60–85 - NCT06094192Recruiting
Brain stimulation to improve memory in Alzheimer's
This study tests whether a gentle, noninvasive brain stimulation technique called tACS can help improve memory in people with Alzheimer's disease or mild cognitive impairment. It may also include healthy older adults for comparison.
Boston, MassachusettsAges 50–100 - NCT06099587Recruiting
Brain scan study for early Alzheimer's memory changes
This study uses a special MRI scan to look at the brain's memory center in people with early memory concerns. It aims to better understand changes that happen in the very early stages of Alzheimer's disease.
RennesAges 50–80 - NCT05336695RecruitingPhase 1/Phase 2
Brain scan study to measure fibrin in Alzheimer’s
This early study (Phase 1/2) uses brain imaging to look for “fibrin” (a blood-clot–related protein) in people with Alzheimer’s disease and related conditions. The goal is to understand whether fibrin changes can be seen on scans and what it might mean for Alzheimer’s.
Boston, MassachusettsAges 55–90 - NCT05245903Recruiting
Test a supplement and track brain changes with wearable sensors
This study tests whether taking nicotinamide riboside (a form of niacin) affects early memory changes in people with mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD). It also uses passive wearable or sensor data (“digital biomarkers”) to measure changes over time.
Belmont, MassachusettsAges 18–89 - NCT06078891Enrolling by invitationEarly Phase 1
BCG vaccine to lower Alzheimer's blood markers
This trial tests whether the BCG vaccine (a tuberculosis vaccine) can lower a blood marker linked to Alzheimer's disease. It is for people aged 70–80 who have slightly elevated p-tau181 levels but still have normal thinking and daily living skills.
JerusalemAges 70–80 - NCT06057909Recruiting
Brain function study in Lewy body and Alzheimer's disease
This study looks at how brain function changes over time in people with Lewy body disease or Alzheimer's. Researchers will use memory tests, MRI scans, and EEG (a painless brain-wave recording) to track these changes, and you will need a family member or friend to help report on your daily life.
Scottsdale, ArizonaAges 50–95 - NCT06052163RecruitingPhase 2
Testing bumetanide for early Alzheimer's disease
This study tests whether a water pill called bumetanide can help people with early Alzheimer's disease. It involves taking the study drug, having MRI scans, and doing memory tests to see if it slows down symptoms.
Stanford, CaliforniaAges 50–85 - NCT06023446Enrolling by invitation
Can eye photos detect early Alzheimer's disease?
This study uses a special camera (OCT) to take pictures of the retina (the back of your eye) to see if it can detect Alzheimer's disease very early. You may be eligible if you are either cognitively normal or have mild cognitive impairment, and have already had a test for Alzheimer's-related brain changes.
Sacramento, CaliforniaAges 50–89 - NCT05995418Recruiting
Cost and health impact study for Alzheimer's in China
This study looks at the financial and health effects of Alzheimer's disease and mild cognitive impairment (aMCI) in China. It aims to understand how the disease affects patients and families over time.
BeijingAges 40–100 - NCT05950607Recruiting
Nursing home study to reduce unnecessary antibiotic use
This study looks at ways to lower how often antibiotics are used in nursing home residents with Alzheimer’s disease and other dementias. It aims to make antibiotic use more appropriate while monitoring resident outcomes.
Boston, MassachusettsAges 60–106 - NCT05926011Recruiting
Test RGn600 in mild to moderate Alzheimer’s patients
This trial studies whether RGn600 can help people with mild to moderate Alzheimer’s disease. You may be able to join if you meet age, test-score, scan, bloodwork, and safety requirements and can attend study visits with a regular caregiver.
CastresAges 55–85
Hear when a new Alzheimer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer?
- Yes. Clin2 currently lists 633 recruiting alzheimer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.